Is there a therapeutic window for metabolism-based cancer therapies?

Frontiers in Endocrinology

Volumn 8, Issue JUL, 2017, Pages

  Fendt, Sarah Maria ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b Katholieke Universiteit   (Belgium)

Author keywords

Cancer; Cancer cells; Endothelial cells; Immune cells; Metabolism; Metastasis formation; Treatment

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; ANTINEOPLASTIC AGENT; PROTEIN ARGININE METHYLTRANSFERASE; SUCCINATE DEHYDROGENASE;

CANCER CELL; CANCER GENETICS; CANCER THERAPY; CELL METABOLISM; CELL PROLIFERATION; DRUG EFFICACY; DRUG TARGETING; GAIN OF FUNCTION MUTATION; HUMAN; IMMUNOCOMPETENT CELL; MALIGNANT NEOPLASM; METABOLISM; NOTE; ONCOGENE; PHENOTYPE; STROMA CELL; THERAPEUTIC INDEX;

EID: 85025465348     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2017.00150     Document Type: Note

References (26)

1. Elia I, Schmieder R, Christen S, Fendt S-M. Organ-specific cancer metabolism and its potential for therapy. Handb Exp Pharmacol (2016) 233:321-53. doi:10.1007/164_2015_10
2. Hanahan D, Weinberg Robert A. Hallmarks of cancer: the next generation. Cell (2011) 144(5):646-74. doi:10.1016/j.cell.2011.02.013
3. Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol (2015) 17(4):351-9. doi:10.1038/ncb3124
4. Pavlova Natalya N, Thompson Craig B. The emerging hallmarks of cancer metabolism. Cell Metab (2016) 23(1):27-47. doi:10.1016/j.cmet.2015.12.006
5. DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res (2008) 68(21):8643. doi:10.1158/0008-5472.CAN-07-6611
6. Iurlaro R, León-Annicchiarico CL, Muñoz-Pinedo C. Regulation of cancer metabolism by oncogenes and tumor suppressors. Methods Enzymol (2014) 542:59-80. doi:10.1016/B978-0-12-416618-9.00003-0
7. Christen S, Lorendeau D, Schmieder R, Broekaert D, Metzger K, Veys K, et al. Breast cancer-derived lung metastasis show increased pyruvate carboxylase-dependent anaplerosis. Cell Rep (2016) 17(3):837-48. doi:10.1016/j.celrep.2016.09.042
8. Hensley CT, Faubert B, Yuan Q, Lev-Cohain N, Jin E, Kim J, et al. Metabolic heterogeneity in human lung tumors. Cell (2016) 164(4):681-94. doi:10.1016/j.cell.2015.12.034
9. Davidson SM, Papagiannakopoulos T, Olenchock BA, Heyman JE, Keibler MA, Luengo A, et al. Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer. Cell Metab (2016) 23(3):517-28. doi:10.1016/j.cmet.2016.01.007
10. Mayers JR, Torrence ME, Danai LV, Papagiannakopoulos T, Davidson SM, Bauer MR, et al. Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science (2016) 353(6304):1161. doi:10.1126/science.aaf5171
11. Elia I, Fendt S-M. In vivo cancer metabolism is defined by the nutrient microenvironment. Transl Cancer Res (2016) 5:S1284-7. doi:10.21037/tcr.2016.11.53
12. Marjon K, Cameron MJ, Quang P, Clasquin MF, Mandley E, Kunii K, et al. MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis. Cell Rep (2016) 15(3):574-87. doi:10.1016/j.celrep.2016.03.043
13. Mavrakis KJ, McDonald ER III, Schlabach MR, Billy E, Hoffman GR, deWeck A, et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5. Science (2016) 351(6278):1208. doi:10.1126/science.aad5944
14. Kryukov GV, Wilson FH, Ruth JR, Paulk J, Tsherniak A, Marlow SE, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science (2016) 351(6278):1214. doi:10.1126/science.aad5214
15. Cardaci S, Zheng L, MacKay G, van den Broek NJ, MacKenzie ED, Nixon C, et al. Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis. Nat Cell Biol (2015) 17(10):1317-26. doi:10.1038/ncb3233
16. Letouzé E, Martinelli C, Loriot C, Burnichon N, Abermil N, Ottolenghi C, et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell (2013) 23:739-52. doi:10.1016/j.ccr.2013.04.018
17. Lorendeau D, Rinaldi G, Boon R, Spincemaille P, Metzger K, Jäger C, et al. Dual loss of succinate dehydrogenase (SDH) and complex I activity is necessary to recapitulate the metabolic phenotype of SDH mutant tumors. Metab Eng (2016). doi:10.1016/j.ymben.2016.11.005
18. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 12(11):829-46. doi:10.1038/nrd4191
19. Elia I, Broekaert D, Christen S, Boon R, Radaelli E, Orth MF, et al. Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat Commun (2017) 8:15267. doi:10.1038/ncomms15267
20. Piskounova E, Agathocleous M, Murphy MM, Hu Z, Huddlestun SE, Zhao Z, et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature (2015) 527(7577):186-91. doi:10.1038/nature15726
21. Cantelmo AR, Conradi LC, Brajic A, Goveia J, Kalucka J, Pircher A, et al. Inhibition of the glycolytic activator PFKFB3 in endothelium induces tumor vessel normalization, impairs metastasis, and improves chemotherapy. Cancer Cell (2016) 30(6):968-85. doi:10.1016/j.ccell.2016.10.006
22. Geeraerts X, Bolli E, Fendt S-M, Van Ginderachter JA. Macrophage metabolism as therapeutic target for cancer, atherosclerosis, and obesity. Front Immunol (2017) 8:289. doi:10.3389/fimmu.2017.00289
23. Phan AT, Goldrath AW, Glass CK. Metabolic and epigenetic coordination of T cell and macrophage immunity. Immunity (2017) 46(5):714-29. doi:10.1016/j.immuni.2017.04.016
24. Tyrakis PA, Palazon A, Macias D, Lee KL, Phan AT, Veliça P, et al. S-2-hydroxyglutarate regulates CD8+ T-lymphocyte fate. Nature (2016) 540(7632):236-41. doi:10.1038/nature20165
25. Dekempeneer Y, Keyaerts M, Krasniqi A, Puttemans J, Muyldermans S, Lahoutte T, et al. Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle. Expert Opin Biol Ther (2016) 16(8):1035-47. doi:10.1080/14712598.2016.1185412
26. Mody VV, Cox A, Shah S, Singh A, Bevins W, Parihar H. Magnetic nanoparticle drug delivery systems for targeting tumor. Appl Nanosci (2014) 4(4):385-92. doi:10.1007/s13204-013-0216-y